Krakow, Poland – March 15, 2023 – Ryvu (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, has been named the Best Company on the Warsaw Stock Exchange for 2022, as a result of a competition organized by “Puls Biznesu” – one of the largest business daily in Poland. Ryvu was the recipient of three other awards: “Investor Relations”, “Development Perspectives”, and “Products and Services Innovation”.
This year marked the 24th edition of the competition, which is the most prestigious ranking in the Polish capital market. Each year, a panel of 100 industry experts, including market analysts, investment advisers, institutional investors, and securities house representatives, select the best companies across five categories: management board competencies, success, products and services innovation, investor relations, and development perspectives.
Ryvu’s recognition as the Best Company of the Year comes after a highly successful 2022, which saw significant progress in its clinical projects, two partnering deals, financial support from the EIB, and a successful public offering.